Download PDF
Thromb Haemost 2008; 99(06): 989-990
DOI: 10.1160/TH08-05-0274
Editorial Focus
Schattauer GmbH

Differences in the safety profiles of two low-molecular-weight heparins

Frederick A. Ofosu
1   Canadian Blood Services and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 01 May 2008

Accepted 06 May 2008

Publication Date:
28 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Grey E, Mulloy B, Barrowcliffe TW. Heparin and low molecular weight heparin. Thromb Haemost 2008; 99: 807-818.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Hull RD, Pineo GF. Low molecular weight heparin in the treatment of venous thromboembolism. Semin Thromb Hemost 2000; 26 (Suppl. 01) 61-67.
    PubMedGoogle Scholar
  • 3 Geerts WH, Heij JT, Clagget GP. et al. Prevention of venous thromboembolism. Chest 2001; 119 (Suppl. 01) 132S-175S.
    CrossrefPubMedGoogle Scholar
  • 4 Ofosu FA. Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thromb Haemost 2006; 96: 568-577.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bounameaux H, De Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 551-558.
    CrossrefPubMedGoogle Scholar
  • 6 Harenberg J. Is laboratory monitoring of low-molecular weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2: 547-550.
    CrossrefPubMedGoogle Scholar
  • 7 Planes A. An equivalence study of two low molecular weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement. Semin Thromb Hemost 2000; 26 (Suppl. 01) 57-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Planes A. Comparison of antithrombotic efficacy and haemorrhagic side-effects of clivarin versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis 1993; 4 (Suppl. 01) 533-535.
    PubMedGoogle Scholar
  • 9 Planes A, Vochelle N, Fagola M. et al. Comparison of two low-molecular-weight heparins for the prevention of post-operative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis 1998; 9: 499-505.
    CrossrefPubMedGoogle Scholar
  • 10 Navarro-Quilis A, Castellet E, Rocha E. et al. Bemiparin Study Group in Knee Artheroplasty. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost 2003; 1: 425-432.
    CrossrefPubMedGoogle Scholar
  • 11 Simmonneau G, Laporte S, Mismetti P. et al. FX140. Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IV (0.3 mL) versus enoxaparin 4000 IV (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 2006; 4: 1693-1700.
    CrossrefPubMedGoogle Scholar
  • 12 Prandoni P. Low molecular weight heparins: are they interchangeable? Yes. J Thromb Haemost 2003; 1: 10-11.
    CrossrefPubMedGoogle Scholar
  • 13 Nenci GG. Low molecular weight heparins: are they interchangeable? No. J Thromb Haemost 2003; 1: 12-13.
    CrossrefPubMedGoogle Scholar
  • 14 Kistler U, Kramers-de Quervain I, Munzinger U. et al. Bleeding complications after systemic switch of routine prophylaxis for major orthopedic surgery. Thromb Haemost 2008; 99: 1049-1052.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
    CrossrefPubMedGoogle Scholar
  • 16 Schellong S, Hesseschwevdt HJ, Paar WD. et al. Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged prophylaxis with low molecular weight heparin after major orthopedic surgery. Thromb Haemost 2005; 94: 532-536.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Arnesen H, Dahl OE, Aspelia T. et al. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost 2003; 1: 971-975.
    CrossrefPubMedGoogle Scholar